Royalty Report: Drugs, Delivery, Disease – Collection: 344522


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Delivery
  • Disease
  • Device
  • Optical
  • Surgical
  • Biotechnology
  • Pain
  • Cancer
  • Therapeutic
  • Viral Infection

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 344522

License Grant
For the License to Product, Licensor grants to the Licensee of Japan, an exclusive license under the Licensor Technology to research, Develop, have Developed, make, have made, use, have used, market, distribute, import, export, lease, sell and offer for sale, promote, sell and have sold Product, in each case for use in the Field in the Territory.
License Property
Licensor owns and controls rights in and to certain technologies and compositions related to and comprising its proprietary injectable, non-polymeric, high viscosity liquid carrier known as the SABER formulation platform technology.

The Active Ingredient shall mean sirolimus.

The Existing Product shall mean those formulations of the Active Ingredient incorporating the SABER® Formulation Platform.

Product shall mean
— any pharmaceutical product incorporating (A) the Active Ingredient as its sole active pharrmaceutical ingredient and the SABER® Formulation Platform; or
— any Existing Product,
in each case formulated for local administration to the eye, including intra-ocular or peri-ocular injection.

SABER Formulation Platform shall mean, Licensors or its Affiliates proprietary (i.e. Covered by Licensor Patents or incorporating Confidential Information of Licensor) injectable non-polymeric, high viscosity liquid carrier system comprising SAIB for imparting controlled release to active ingredients.

SABER Technology is a patented technology designed to provide sustained release, bioerodible injectable depot systems.

Field of Use
The Field shall mean the treatment, mitigation or preventions of diseases, disorders or conditions of the eye.

IPSCIO Record ID: 209498

License Grant
Licensor grants
– the exclusive right and license to make and have made, use, offer for sale, sell and import the Product in the Field and in the Territory, including the right to record sales for its own account; in each case, solely for use in the Field and Territory and to develop and Commercialize the Product and to otherwise exercise Licensee’s rights and perform its obligations under this Agreement,
– an exclusive license under the Licensor Technology, the Licensor Technology Patents (including Product Specific Patent Rights) and Licensor’s rights in the Joint Technology, Joint Patent Rights, Other Project Technology and Patents, and
– an exclusive license and the right of use and cross-reference to all Development Data Controlled by Licensor solely to exercise Licensee’s granted rights.

Licensee shall have the right to select the Product names and all trademarks used in connection with the marketing, promotion and Commercialization of the Product.

Licensee has rights to sublicense.

License Property
Active Agent means risperidone in free base form and all pharmaceutically accetable salts.

Licensor Technology means any and all Know-How Controlled by Licensor or any of its Affiliates at any time during the Term which relates in whole or in part to polymeric and/or non-polymeric carrier materials and systems (including the SABERâ„¢ Formulation Platform and the ALZA patent rights for imparting controlled release or other performance-enhancing qualities to products, including any combination or use of such materials or systems with the Active Agent; and Licensor Project Technology, in each case, to the extent relevant to the manufacture, use or sale of Product in the Field and in the Territory.

ALZA patents relate to Sustained Release Small Molecule Drug Formulation.

Field of Use
The Field means the treatment of schizophrenia, bipolar disorder or other psychiatric related disorders in humans.

IPSCIO Record ID: 26586

License Grant
Licensee shall have the exclusive right to Commercialize each of the Licensed Products in the Territory.  Saber Delivery System a patented and versatile depot injectable useful for protein and small molecule delivery that can be formulated for systemic or local administration.
License Property
The advantages of Saber may include reduced side effects, longer duration and smaller injection volume. Our first application is for controlled delivery of bupivacaine for post-operative pain relief (Saber-Bupivacaine), for which we own all worldwide rights. Saber-Bupivacaine is currently in Phase II clinical trials. We are developing Saber-Bupivacaine, a sustained-release formulation of bupivacaine, a local anesthetic, using our Saber delivery system for the treatment of post-surgical pain.

IPSCIO Record ID: 230818

License Grant
Licensor agrees to collaborate with the Swiss Licensee to conduct a research program with respect to the Drug Product.

Licensor grants to the Swiss Licensee, the non-transferable, sole and exclusive right and license under the Licensor Patent Rights and Licensor Technology, with the right to grant sublicenses, to the extent necessary to develop, manufacture, market, import, use or sell the Drug Product within the Field throughout the Territory.

Licensor grants an irrevocable, sole and exclusive right and option to acquire an exclusive license under the Licensor Patent Rights and Licensor Technology to develop, manufacture, market, import, use or sell the Other Product in the Territory during the Term.

License Property
Licensor is engaged in the research, development and manufacture of controlled-release drug delivery products.

Licensor Technology means any and all Technical Information related to the SABERâ„¢ Delivery System, which is owned, possessed, developed or acquired by or licensed to Licensor or its Affiliates as of the Effective Date or during the Term and all Licensor Inventions, to which Licensor has the right to grant licenses or sublicenses hereunder.

SABERâ„¢ Delivery System means Licensors SABERâ„¢ delivery system for imparting controlled release of drug active ingredients in the Field.

Field of Use
Field means the use of the Drug Product for the therapeutic areas of virology and oncology.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.